Oxford Spinout Secures £20.75M in Oversubscribed Funding

Oxford University Spinout Secures £20.75 Million in Oversubscribed Funding Round

Oxford University spinout, OxNoxis, has successfully closed an oversubscribed funding round, raising £20.75 million. The investment signifies a significant milestone for the company, which is focused on developing a novel treatment for cancer.

The funding round was led by Panakaj Mehta, a private investor, and saw participation from a range of other investors. OxNoxis aims to utilize the newly acquired capital to advance its lead drug candidate into clinical trials and expand its research and development capabilities.

OxNoxis is developing a new therapeutic approach to combat cancer. The company’s technology is based on groundbreaking research originating from Oxford University, a renowned institution for scientific innovation.

The successful closure of this substantial funding round underscores the confidence investors have in OxNoxis’s potential to deliver a breakthrough in cancer treatment. The company’s team is committed to translating its scientific advancements into tangible benefits for patients.

Key Points

• £20.75 million raised
• Funding round was oversubscribed

Read the Complete Article.